Menu
Recruiting NCT07328178

Analysis of the Role of IgE Proteoforms in Health and Disease

— Observational Anaphylaxis Mastocytosis X-linked Agammaglobulinaemia Venom Allergy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood sample collection.
Who it may be relevant to
Registry conditions: Anaphylaxis, Mastocytosis, X-linked Agammaglobulinaemia, Venom Allergy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.

Interventions

  • Other Blood sample collection
    Blood sample collection

Primary outcome measures

  • Evaluation of IgE proteoforms [Time frame: 4 years]

Eligibility criteria

Inclusion criteria

  • CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)
  • Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)

Exclusion criteria

  • Absence of informed consent
  • Age < 18 years old

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Belgium · 1 center
  • UZ/KU Leuven — Leuven

Identifiers

NCT: NCT07328178 · S69940

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗